Drug testing puts consumers at risk

Share this article:
A sociologist says fatal flaws in the way new drugs are tested and marketed mean that American consumers are likely to be exposed to unacceptable side effects of FDA-approved drug such as Vioxx in the future.

In a study presented at the American Sociological Association annual meeting, University of Medicine and Dentistry of New Jersey professor of comparative health policy Donald Light said disasters “are literally built into the current system of drug testing and approvals in the US.”

A release on Light's paper said his analysis identifies the organizational foundations of patient risk from Rx drugs and suggests reforms to help avoid or reduce drug disasters. Light said that rather than using current approved drugs as benchmarks of efficacy, the current drug system evaluates effectiveness based on comparisons with placebos. Systematic review indicates, he said, that one in seven new drugs is superior to existing drugs, but two in every seven new drugs result in side effects serious enough for action, including black-box warnings or withdrawal from the market.

New drugs are twice as likely to harm patients as to provide them with benefits superior to existing drugs, Light asserted. His analysis also suggested a flaw in clinical trial design.  

“Based on our current system, the designation of ‘safe and effective' on today's new drugs could be replaced with ‘apparently safe based on incomplete information, and more effective than a placebo,'” Light said. 
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters

More in Features

Journal Ad Review: Reality Bites

Journal Ad Review: Reality Bites

Print's numbers may be taking some small steps in the right direction, but data is what the industry really wants to sink its teeth into. Larry Dobrow reports on what ...

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...